Drugmaker Wyeth is suing the Food and Drug Administration to block India’s Orchid Chemicals & Pharmaceuticals from a selling a generic version of Zosyn, a powerful antibiotic used in intensive care medicine.
The lawsuit claims the FDA’s approval of Orchid’s generic products is “unlawful” and “arbitrary, capricious, an abuse of discretion,” adding that it “permits the marketing of a generic drug product that cannot be safely used in the same manner as the branded product’’ and “seriously endangers patient health.”
Wyeth markets a newer version of the drug and in 2005 discontinued the older version of Zosyn, known chemically as piperacillin and tazobactam, which Orchid has now secured permission from the FDA to sell.
Please Note: Entering Incorrect Security Code After The Comment Box Will Cause No Submission Of Data. Please read instructions at end before Submitting the comment.
Please enter the Case Sensitive Security Code that you see in image in the box above before Submitting the Comment. Upon successful submission, the form above would disappear.
You may submit lengthier letters to the editor using the Feedback Form
